Global Blood Therapeutics Inc (GBT)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Ted W. Love
Employees:
460
400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO, CA 94080
650741-7700

Global Blood Therapeutics, Inc. engages in the discovery, development, and delivery of treatments for sickle cell disease (SCD) The company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions. The company offers Oxbryta tablets, an oral, once-daily therapy for SCD.

Data derived from most recent annual or quarterly report
Market Cap 4.44 Billion Shares Outstanding64.82 Million Avg 30-day Volume 2.772 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-1.26
Price to Revenue8.9234 Debt to Equity4.9167 EBITDA-287.658 Million
Price to Book Value17.7066 Operating Margin-127.41279999999999 Enterprise Value2.014 Billion
Current Ratio6.875 EPS Growth-0.16 Quick Ratio5.875
1 Yr BETA 1.0349 52-week High/Low 73.02 / 21.65 Profit Margin-137.2991
Operating Cash Flow Growth-19.1372 Altman Z-Score-0.7759 Free Cash Flow to Firm -218.079 Million
View SEC Filings from GBT instead.

View recent insider trading info

Global Blood Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding GBT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding GBT

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2022-10-06 by PERRY MARK L
  • 4: filed on 2022-10-06 by PATRICK DEVAL L
  • 4: filed on 2022-10-06 by MORRISON SCOTT W
  • 4: filed on 2022-10-06 by THOMPSON ALEXIS A.
  • 4: filed on 2022-10-06 by YARNO WENDY L
  • 4: filed on 2022-10-06 by PIZZO PHILIP A.
  • 4: filed on 2022-10-06 by SVORONOS DAWN
  • 4: filed on 2022-10-06 by PIERCE GLENN
  • 4: filed on 2022-10-06 by SMITH-WHITLEY KIM
  • 4: filed on 2022-10-06 by JOHNSON DAVID LEE

    • Events (8k)

  • 8-K: filed on 2022-10-05:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-30:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 8.01: Other Events
  • 8-K: filed on 2022-09-23:
    Item 8.01: Other Events
  • 8-K: filed on 2022-08-08:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 1.01: Entry into a Material Definitive Agreement
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-26:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-14:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-29:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-15:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-06-13:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-10:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    PATRICK DEVAL L

    • Director
    		 0 2022-10-05 2

    YARNO WENDY L

    • Director
    		 0 2022-10-05 2

    LOVE TED W PRESIDENT AND CEO

    • Officer
    • Director
    		 0 2022-10-05 4

    PERRY MARK L

    • Director
    		 0 2022-10-05 2

    SUVARI TRICIA BORGA CHIEF LEGAL OFFICER

    • Officer
    		 0 2022-10-05 3

    PIERCE GLENN

    • Director
    		 0 2022-10-05 2

    FARROW JEFFREY S CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2022-10-05 4

    PIZZO PHILIP A.

    • Director
    		 0 2022-10-05 3

    SVORONOS DAWN

    • Director
    		 0 2022-10-05 3

    CHOI JUNG SEE REMARKS

    • Officer
    		 0 2022-10-05 4

    MORRISON SCOTT W

    • Director
    		 0 2022-10-05 2

    JOHNSON DAVID LEE CHIEF COMMERCIAL OFFICER

    • Officer
    		 0 2022-10-05 3

    KREHLIK CARRIE CHIEF HUMAN RESOURCES OFFICER

    • Officer
    		 0 2022-10-05 2

    THOMPSON ALEXIS A.

    • Director
    		 0 2022-10-05 2

    SMITH-WHITLEY KIM SEE REMARKS

    • Officer
    		 0 2022-10-05 3

    HABIBIZAD NAZILA SEE REMARKS

    • Officer
    		 0 2022-10-05 6

    BROWN WILLIE L. JR.

    • Director
    		 48,465 2021-06-17 0

    FINK ERIC CHIEF HUMAN RESOURCES OFFICER

    • Officer
    		 5,161 2021-05-10 0

    CATHERS BRIAN EDWIN CHIEF SCIENTIFIC OFFICER

    • Officer
    		 75,820 2021-03-01 0

    CALHOUN LESLEY ANN SEE REMARKS

    • Officer
    		 154 2020-05-26 0

    LEHRER-GRAIWER JOSHUA CHIEF MEDICAL OFFICER

    • Officer
    		 2,595 2020-03-05 0

    HOMCY CHARLES J

    • Director
    		 0 2018-06-20 0

    PERCEPTIVE ADVISORS LLC

    PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

    EDELMAN JOSEPH

    • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
    		 No longer subject to file 2018-03-08 0

    SHAM HING SEE REMARKS

    • Officer
    		 98,215 2018-03-07 0

    RADOVICH PETER SEE REMARKS

    • Officer
    		 8,833 2018-02-14 0

    THIRD ROCK VENTURES II, L.P.

    THIRD ROCK VENTURES GP II, L.P.

    TRV GP II, LLC

    LEVIN MARK J

    TEPPER ROBERT I

    STARR KEVIN P

    • 10% Owner
    		 No longer subject to file 2017-06-14 0

    TEPPER ROBERT I

    • 10% Owner
    		 4,990,677 2017-04-06 0

    THIRD ROCK VENTURES II, L.P.

    THIRD ROCK VENTURES GP II, L.P.

    TRV GP II, LLC

    THIRD ROCK VENTURES III, L.P.

    THIRD ROCK VENTURES GP III, L.P.

    TRV GP III, LLC

    LEVIN MARK J

    TEPPER ROBERT I

    STARR KEVIN P

    • 10% Owner
    		 420,253 2017-03-02 0

    STARR KEVIN P

    • 10% Owner
    		 8,843,448 2016-12-16 0

    RAMOS ELEANOR CHIEF MEDICAL OFFICER

    • Officer
    		 0 2016-09-29 0

    BONNEY MICHAEL W

    • Director
    		 0 2016-06-16 0

    SCHEMBRI JOHN SEE REMARKS

    • Officer
    		 0 2016-03-10 0

    THIRD ROCK VENTURES II, L.P.

    THIRD ROCK VENTURES GP II, L.P.

    TRV GP II, LLC

    LEVIN MARK J

    TEPPER ROBERT I

    • 10% Owner
    		 12,475,191 2015-08-17 0

    THIRD ROCK VENTURES III, L.P.

    THIRD ROCK VENTURES GP III, L.P.

    TRV GP III, LLC

    LEVIN MARK J

    TEPPER ROBERT I

    • 10% Owner
    		 2,285,713 2015-08-17 0

    THIRD ROCK VENTURES II, L.P.

    THIRD ROCK VENTURES GP II, L.P.

    TRV GP II, LLC

    THIRD ROCK VENTURES III, L.P.

    THIRD ROCK VENTURES GP III, L.P.

    TRV GP III, LLC

    LEVIN MARK J

    TEPPER ROBERT I

    • 10% Owner
    		 571,428 2015-08-11 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    GLOBAL BLOOD THERAPEUTICS IN GBT 2022-10-05 20:15:04 UTC 2.8163 0.2537 2400000
    GLOBAL BLOOD THERAPEUTICS IN GBT 2022-10-05 19:45:04 UTC 2.8163 0.2537 2400000
    GLOBAL BLOOD THERAPEUTICS IN GBT 2022-10-05 19:15:04 UTC 2.8163 0.2537 2400000
    GLOBAL BLOOD THERAPEUTICS IN GBT 2022-10-05 18:45:03 UTC 2.8163 0.2537 2400000
    GLOBAL BLOOD THERAPEUTICS IN GBT 2022-10-05 18:15:03 UTC 2.8163 0.2537 2400000
    GLOBAL BLOOD THERAPEUTICS IN GBT 2022-10-05 17:45:03 UTC 2.8163 0.2537 2400000
    GLOBAL BLOOD THERAPEUTICS IN GBT 2022-10-05 17:15:03 UTC 2.8163 0.2537 2400000
    GLOBAL BLOOD THERAPEUTICS IN GBT 2022-10-05 16:45:04 UTC 2.8163 0.2537 2400000
    GLOBAL BLOOD THERAPEUTICS IN GBT 2022-10-05 16:15:03 UTC 2.8163 0.2537 2400000
    GLOBAL BLOOD THERAPEUTICS IN GBT 2022-10-05 15:45:03 UTC 2.8163 0.2537 900000
    GLOBAL BLOOD THERAPEUTICS IN GBT 2022-10-05 15:15:03 UTC 2.8163 0.2537 900000
    GLOBAL BLOOD THERAPEUTICS IN GBT 2022-10-05 14:45:03 UTC 2.8163 0.2537 900000
    GLOBAL BLOOD THERAPEUTICS IN GBT 2022-10-05 14:15:03 UTC 2.8163 0.2537 900000
    GLOBAL BLOOD THERAPEUTICS IN GBT 2022-10-05 13:45:03 UTC 2.8163 0.2537 900000
    GLOBAL BLOOD THERAPEUTICS IN GBT 2022-10-05 13:15:03 UTC 2.8163 0.2537 900000
    GLOBAL BLOOD THERAPEUTICS IN GBT 2022-10-05 12:45:03 UTC 2.8163 0.2537 900000
    GLOBAL BLOOD THERAPEUTICS IN GBT 2022-10-04 22:15:03 UTC 2.8163 0.2537 850000
    GLOBAL BLOOD THERAPEUTICS IN GBT 2022-10-04 21:45:03 UTC 2.8163 0.2537 850000
    GLOBAL BLOOD THERAPEUTICS IN GBT 2022-10-04 21:15:03 UTC 2.8163 0.2537 850000
    GLOBAL BLOOD THERAPEUTICS IN GBT 2022-10-04 20:45:04 UTC 2.8163 0.2537 850000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    American Century Quantitative Equity Funds, Inc.- AC Alternatives Disciplined Long Short Fund GBT -1104.0 shares, $-87756.96 2019-12-31 N-PORT
    Trust for Professional Managers- Convergence Market Neutral Fund GBT -1028.0 shares, $-64537.84 2020-08-31 N-PORT
    FundVantage Trust- Gotham Master Neutral Fund GBT -18.0 shares, $-992.52 2020-09-30 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund GBT -1.0 shares, $-51.09 2020-03-31 N-PORT
    JNL Series Trust- JNL/AQR Large Cap Relaxed Constraint Equity Fund GBT -9326.0 shares, $-380034.5 2021-03-31 N-PORT
    Prudential Investment Portfolios 12- PGIM QMA Large-Cap Core Equity Plus Fund GBT -1400.0 shares, $-49028.0 2021-06-30 N-PORT
    Prudential Investment Portfolios 12- PGIM QMA Long-Short Equity Fund GBT -3700.0 shares, $-94276.0 2021-09-30 N-PORT
    Advanced Series Trust- AST QMA U.S. Equity Alpha Portfolio GBT -22800.0 shares, $-580944.0 2021-09-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments